What is the Bal Pharma PE ratio today?
Bal Pharma's PE ratio is 18.7 at the 29 October 2026 close (₹84.61 a share): a market capitalisation of ₹135 crore divided by consolidated net profit of ₹7.2 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹6.3 crore) it is 21.4.
What is the Bal Pharma net worth?
Bal Pharma's net worth — shareholders' equity in its consolidated balance sheet — was ₹82.2 crore on 31 March 2026, up 6.2% from ₹77.4 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹135 crore at the 29 October 2026 close.
What is the Bal Pharma book value per share?
Bal Pharma's book value per share was ₹51.65 on 31 March 2026: shareholders' equity of ₹82.2 crore divided by the 1.59 crore shares in issue, up 6.2% from ₹48.63 a year earlier. The share price at the 29 October 2026 close was ₹84.61.
What is the Bal Pharma PB ratio (price to book value)?
Bal Pharma's price-to-book (PB) ratio is 1.64 at the 29 October 2026 close: a market capitalisation of ₹135 crore divided by shareholders' equity (book value) of ₹82.2 crore on 31 March 2026. That is a book value of ₹51.65 per share against a share price of ₹84.61.
What is the Bal Pharma ROE and ROCE?
In FY26, Bal Pharma's return on equity (ROE) was 7.9% and its return on capital employed (ROCE) was 17.2%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 9.8% and ROCE 17.0%.
What is the Bal Pharma dividend yield?
Bal Pharma's dividend yield is 1.42% at the 29 October 2026 close: dividends of ₹1.20 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹84.61. They were ₹1.20 on 17 September 2026.
What is the Bal Pharma market cap?
Bal Pharma's market capitalisation was ₹135 crore at the 29 October 2026 close: 1.59 crore shares at ₹84.61 each.
What is the Bal Pharma EPS?
Bal Pharma's basic earnings per share (EPS) were ₹3.95 in FY26, against ₹4.56 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹4.54.
What is the Bal Pharma dividend in 2026 and its record date?
In 2026, Bal Pharma has declared one dividend: ₹1.20 with record date 17 September 2026.
Is Bal Pharma debt free?
No. Bal Pharma had borrowings of ₹160 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 1.94. Its cash and current investments were ₹5.5 crore, so its net debt was ₹154 crore.
What is the Bal Pharma debt to equity ratio?
Bal Pharma's debt-to-equity ratio was 1.94 on 31 March 2026: borrowings of ₹160 crore against total equity of ₹82.3 crore. A year earlier, on 31 March 2025, it was 1.94.
What is the Bal Pharma promoter holding?
Promoters held 50.86% of Bal Pharma on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.
What is the Bal Pharma shareholding pattern?
On 30 September 2026, Bal Pharma's shares were held by promoters 50.86%, foreign portfolio investors (FII/FPI) 0.28% and retail and other non-institutional investors 48.87%. Over the year, FII holding was up 0.06 percentage points from 0.22%.
What is the Bal Pharma free cash flow?
In FY26, Bal Pharma generated ₹30.8 crore of cash from operations and spent ₹18.6 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹12.3 crore. In FY25 it was ₹20.7 crore.
What are the Bal Pharma latest quarterly results?
Bal Pharma's latest results are for Q1 FY27 (April–June 2026), filed on 12 August 2026: consolidated net profit ₹1.1 crore, up 438.8% from ₹21 lakh in Q1 FY26; revenue from operations ₹88.6 crore, up 34.5% year on year.
What is the Bal Pharma revenue and profit in FY26?
In FY26 (April 2025–March 2026), Bal Pharma's consolidated net profit was ₹6.3 crore, down 12.9% from ₹7.2 crore in FY25, on revenue from operations of ₹312 crore (up 2.8%). Over three years, from FY23, net profit was up 139.9%.
When are the Bal Pharma next results?
Bal Pharma has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.
How does Bal Pharma compare with its peers?
On FY26 consolidated figures, against Alpa Laboratories, Krebs Biochemicals and Industries and Natural Capsules: Bal Pharma's operating margin of 6.7% is the highest of the four (Alpa Laboratories 1.1%, Krebs Biochemicals and Industries −50.0%, Natural Capsules −10.0%; peer average −19.6%).
Bal Pharma vs Alpa Laboratories: how do they compare?
In FY26, Bal Pharma earned net profit of ₹6.3 crore on revenue of ₹312 crore, against ₹15 crore on ₹106 crore for Alpa Laboratories. Bal Pharma's operating margin was 6.7% (Alpa Laboratories 1.1%) and its return on equity 7.9% (Alpa Laboratories 8.4%). At the 29 October 2026 close, Bal Pharma's market capitalisation was ₹135 crore against ₹111 crore for Alpa Laboratories, and its PE ratio on FY26 profit 21.4 against 7.4.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
